Thyroid cancer diagnostics refers to a technique to test a lump or nodule responsible for thyroid cancer present in the body and helps in diagnosing thyroid cancer. Thyroid cancer refers to a type of cancer that starts in the thyroid gland when cells begin to grow out of control.
Sizing and Forecast
The thyroid cancer diagnostics market size has grown strongly in recent years. It will grow from $2.79 billion in 2023 to $2.97 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing prevalence of thyroid cancer, aging population, rising awareness and early detection, government initiatives and funding, improved healthcare infrastructure..
The thyroid cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $3.7 billion in 2028 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to growing demand for companion diagnostics, increasing patient preference for personalized medicine, economic growth and healthcare spending, physician education and training, regulatory approvals and clearances.. Major trends in the forecast period include liquid biopsies, globalization of diagnostic technologies, technological advancements, research and development, integration of artificial intelligence, collaborations and partnerships.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/thyroid-cancer-diagnostics-global-market-report
Segmentation & Regional Insights
The thyroid cancer diagnostics market covered in this report is segmented –
1) By Technique Type: Imaging Test, Blood Test, Biopsy, Other Test Type
2) By Disease Type: Papillary Carcinoma, Follicular Carcinoma, Other Diseases
3) By End-User: Hospital Laboratories, Cancer Diagnostic Centers, Research Institutes, Other End-Users
North America was the largest region in the thyroid cancer diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thyroid cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12030&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of thyroid cancer is driving the growth of the thyroid cancer diagnostic market going forward. Thyroid cancer is a disease in the thyroid gland (a gland near the base of the throat that produces hormones to help regulate body temperature, heart rate, blood pressure, and weight). Thyroid cancer diagnostics help to discover thyroid cancer by providing early detection that can help improve treatment outcomes. Thus, the increasing prevalence of thyroid cancer increases the demand for the diagnostic market. For instance, in September 2023, according to a report published by the American Cancer Society, a US-based non-profit organization, there are anticipated to be approximately 43,720 new cases of thyroid cancer, with 12,540 occurring in men and 31,180 in women in 2023. The projected number of deaths from thyroid cancer in the same year is around 2,120, with 970 in men and 1,150 in women. Therefore, thyroid cancer’s increasing prevalence is propelling the diagnostic market of thyroid cancer.
Key Industry Players
Major companies operating in the thyroid cancer diagnostics market report are Pfizer Inc., General Electric, F. Hoffmann-La Roche AG, Bayer AG, Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, GlaxoSmithKline plc, Canon Inc., Eli Lilly and Company, Toshiba Corporation, Merck KGaA, Siemens Healthcare GmbH, FUJIFILM Holdings Corporation, Koninklijke Philips N.V., GE Healthcare, AstraZeneca plc, Agilent Technologies Inc., Hologic Inc., Genzyme Corporation, Illumina Inc., BioMérieux SA, Bio-Rad Laboratories Inc., Quest Diagnostics Inc., Qiagen N.V., Cepheid, Veracyte Inc., DiaSorin S.p.A., Myriad Genetics Inc.
The thyroid cancer diagnostics market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
